Abstract: The present invention encompasses compounds or Formula (I): as well as the pharmaceutically acceptable salts and hydrates thereof. The compounds are useful for treating immune mediated diseases and conditions, such as bone marrow, organ and tissue transplant rejection. Pharmaceutical compositions and methods of use are included.

Abstract: Compounds of formula (I): or pharmaceutically acceptable salts or solvates thereof, and their use as pharmaceuticals, particularly as p38 kinase inhibitors.

Abstract: The present invention relates to compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein the R1, Z, Y, RA, and W groups of formula I are as defined herein. The invention also provides pharmaceutically acceptable compositions and methods of using the compositions in the treatment of various disorders.

Abstract: Substituted thiazolidinone carboxylic acid amides and substituted thiazolidine carboxylic acid amides according to formulae (I) and (II) are disclosed where the various substituent groups are as defined in the specification. Methods of making these compounds, pharmaceutical compositions containing the compounds, and their use, particularly for treating or preventing cancer, are also disclosed.

Abstract: The present invention provides compounds, compositions and methods for the selective inhibition of cathepsin S. In a preferred aspect, cathepsin S is selectively inhibited in the presence of at least one other cathepsin isozyme. The present invention also provides methods for treating a disease state in a subject by selectively inhibiting cathepsin S.

Abstract: A microencapsulated Group VIII metal catalyst which is stable even in air, easy to recover, and reusable is disclosed. It comprises a polymer with side chains containing an aromatic substituent, and a metal catalyst comprising a Group VIII metal encapsulated in to this polymer.

Abstract: Novel phosphonium salts of benzotraizoles, which are highly reactive coupling agents, and are particularly useful in peptide synthesis, are disclosed. Further disclosed is a process of preparing the novel phosphonium salts and methods utilizing same for preparing peptides.

Abstract: The present invention concerns a method of treatment or prevention of myocardial ischemia-reperfusion injury by diagnosing that a person is in need of treatment or prevention of myocardial ischemia-reperfusion injury and administering a therapeutically effective amount of a ligand which modulates NF-kB transcription factor by interaction with estrogen receptor ER-?, estrogen receptor ER-?, or both ER-? and ER-? estrogen receptors with a substantial absence of creatine kinase stimulation. In certain preferred embodiments, the administration is substantially without uterotropic activity.

Abstract: It has now been found that certain novel N-(substituted aryl)-4(disubstituted methyl)piperidine and pyridine derivatives have provided unexpected insecticidal activity. These compounds are represented by formula (I): wherein m, n, q, r, and s are independently selected from 0 or 1; and p is 0, 1, 2, or 3; A is C or CH; and B, D, E, R, R1, R2, R3, R4, R5, R6, R7 and R8 are fully described herein.

Abstract: The present invention relates to novel arylphenyl-substituted cyclic ketoenols of the formula (I) in which X represents halogen, alkyl, alkoxy, alkenyloxy, alkylthio, alkylsulphinyl, alkylsulphonyl, halogenoalkyl, halogenoalkoxy, halogenoalkenyloxy, nitro, cyano or in each case optionally substituted phenyl, phenoxy, phenylthio, phenylalkoxy or phenylalkylthio, Y represents in each case optionally substituted cycloalkyl, aryl or hetaryl, Z represents hydrogen, halogen, alkyl, alkoxy, alkenyloxy, halogenoalkyl, halogenoalkoxy, halogenoalkenyloxy, nitro or cyano, CKE represents one of the groups in which A, B, D, G and Q1 to Q6 are each as defined in the description, to a plurality of processes for their preparation and to their use as pesticides and herbicides.

Abstract: The present invention relates to compounds of formula I their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, medicaments containing them and their manufacture, as well as the use of the above-mentioned compounds in the control or prevention of illnesses such as cancer.

Abstract: Disclosed herein are a cosmetic composition comprising at least one diazirine active-agent compound comprising a diazirine covalently bonded to a cosmetic active agent, said at least one diazirine-active agent compound and the uses of the composition or of the compound, as well as cosmetic treatment processes using the composition or the compound.

Abstract: Novel biaromatic compounds having the structural formula (I) below: are formulated into pharmaceutical compositions suited for administration in human or veterinary medicine (in dermatology, and also in the fields of cardiovascular diseases, immune diseases and/or diseases associated with lipid metabolism), or, alternatively, into cosmetic compositions.

Abstract: The invention relates to 4-cyanopyrazole-3-carboxamide derivatives of formula (I): in which R1, R2, R3, R4, R5, R6, R7, R8 are as described herein. Also disclosed and claimed are the method of preparation and therapeutic application of compound of formula (I).

Abstract: The invention describes novel nitrosated and/or nitrosylated diuretic compounds or pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated and/or nitrosylated diuretic compound, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides novel compositions and kits comprising at least one diuretic compound of the invention, that is optionally nitrosated and/or nitrosylated, and, optionally, at least one nitric oxide donor compound and/or at least one therapeutic agent.

Abstract: The present invention relates to inhibitors of protein kinases. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.

Abstract: An industrially advantageous process is presented whereby a high purity anthracene diether can be produced in good yield. An aqueous medium containing an alkali salt of 9,10-anthracenediol is added to an organic solvent containing an etherifying agent in the presence or absence of a quaternary ammonium compound or a quaternary phosphonium compound, to carry out the etherifying reaction to produce the anthracene diether.

Abstract: A process for the production of dialkyl carbonates from the reaction of alcohol, for example C1-C3 alcohols, with urea is disclosed wherein the water and ammonium carbamates impurities in the feed are removed in a prereactor. The water is reacted with urea in the feed to produce ammonium carbamate which is decomposed along with the ammonium carbamates originally in the feed to ammonia and carbon dioxide. In addition some of the urea is reacted with the alcohol in the first reactor to produce alkyl carbamate which is a precursor to dialkyl carbonate. Dialkyl carbonates are produced in the second reaction zone. The undesired by-product N-alkyl alkyl carbamates are continuously distilled off from the second reaction zone along with ammonia, alcohol and dialkyl carbonates under the steady state reactor operation. N-alkyl alkyl carbamates can be converted to heterocyclic compounds in a third reaction zone to remove as solids from the system.

Abstract: The present invention relates to a process for the preparation of a compound of the general formula R-(A1-Z-)mB—CF2O-A2-(A3)n—R???(I) in which R is alkyl, in which one or more CH2 groups may be replaced, independently of one another, by O, CF2, CH?CH, CH?CF or CF?CF, with the proviso that peroxide structures O—O and formaldehyde acetals O—CH2—O are excluded, A1 is, independently of one another, 1,4-cyclohexylene, 2,5-1,3-dioxanylene, 1,3-cyclobutylene or A2 and A3 are 1,4-phenylene, in which, independently of one another, from one to four hydrogens may be replaced by fluorine or one or two CH groups may be replaced by N, Z is a single bond, —CH2—CH2—, —CF2—CF2—, —CH?CH—, —CF?CF—, —CH?CF— or —CF?CH—, B is 2,6-disubstituted naphthalene, 2,6-disubstituted 5,6,7,8-tetrahydronaphthalene or 2,6-disubstituted trans-decalin, R? is R, F, OCF3, OCF2H, CF3, CI, SF5, CN or NCS, and m and n are, independently of one another, 0 or 1, comprising the following steps: a) conversion of a compound of the genera

Abstract: A catalyst for the preparation of dimethyl carbonate from urea and methanol having a composition on weight base of: active component of from 20 to 50 wt %, and carrier of from 80 to 50 wt %, and prepared by equal-volume spraying and impregnating method is disclosed. The method for the synthesis of dimethyl carbonate can be carried out in a catalytic rectification reactor, said method comprising: (1) dissolving urea in methanol to form a methanol solution of urea; and (2) feeding the methanol solution of urea and methanol counter-currently into the reaction zone, wherein the reaction is carried out at conditions including reaction temperature of from 120° C. to 250° C., reaction pressure of from 0.1 MPa to 5 MPa, kettle bottom temperature of from 70° C. to 210° C., stripping section temperature of from 70° C. to 250° C., rectifying section temperature of from 70° C. to 280° C., and reflux ratio of from 1:1 to 20:1.